Foundayo vs the Wegovy pill: two daily tablets, one big practical difference
The UK now has two daily oral GLP-1 tablets. They look similar on paper, but the way you have to take them differs enormously, and for most people that is the deciding factor.
| Foundayo | Wegovy pill | |
|---|---|---|
| Active ingredient | Orforglipron | Semaglutide |
| Molecule type | Small molecule | Peptide |
| Food and water rules | None. Any time of day, with or without food | Empty stomach, limited water, wait before eating or drinking |
| Timing flexibility | Whenever suits you | Structured around your morning |
| Manufacturer | Eli Lilly | Novo Nordisk |
| Swallowing | Whole, do not break, crush or chew | Whole, do not break, crush or chew |
| UK prices | Compare on Dayo | Compare live prices on Ogovy |
Last reviewed: 23 August 2026
The difference that actually changes your day
The Wegovy tablet must be taken on an empty stomach with only a small amount of water, after which you wait before eating or drinking anything else. That is a real constraint. It shapes your mornings, it is easy to get wrong, and getting it wrong can affect how much medicine your body absorbs.
Foundayo has none of those rules. Any time of day, with or without food, with a normal drink. That is the headline practical difference, and for people whose mornings are chaotic, whose shifts rotate, or who simply know themselves well enough to predict how a fiddly routine will go, it is decisive.
Why the rules differ: peptide versus small molecule
Semaglutide is a peptide, and peptides are broken down by the digestive system. To survive the stomach in tablet form, the Wegovy pill relies on absorption conditions that only hold on an empty stomach, hence the rules. Orforglipron is a small molecule, structurally more robust through the gut, so it does not need protecting in the same way. This is not marketing spin; it is the reason one tablet has food rules and the other does not.
Effectiveness: no head-to-head trial exists
Be wary of anyone telling you confidently which tablet works better. There is no direct head-to-head study of orforglipron against oral semaglutide, so any comparison is between separate trials with different designs and populations, which is not a fair fight.
What we can say honestly: Foundayo's ATTAIN-1 trial showed 11.1% average weight loss at the 17.2 mg dose over 72 weeks, against 2.1% on placebo, with ATTAIN-2 showing 9.6% in adults with type 2 diabetes. The Wegovy tablet has its own published evidence base, covered on Ogovy. A prescriber weighing both will look at your history rather than the headline percentages.
Side effects and tolerability
Both are GLP-1 medicines with gut-dominated side effect profiles: nausea, constipation, diarrhoea, indigestion, worst around starting and each dose step, generally settling as the body adjusts. Both carry the GLP-1 class thyroid warning. Community reports of switching between oral GLP-1s go both ways on which is easier to tolerate, which tells you it is individual rather than settled. Our side effects map details Foundayo's profile with the trial frequencies.
Which suits which person
- Foundayo suits unpredictable schedules, shift work, frequent travel, anyone who eats or drinks early, and anyone who knows a strict morning routine will not survive contact with real life.
- The Wegovy pill suits people with a settled morning routine who can reliably keep the empty-stomach window, and anyone whose prescriber has a specific reason to prefer semaglutide, including existing familiarity with it.
Comparing the whole field
These two are not the only options: the weekly injections often show larger average weight loss. Our Foundayo vs Mounjaro comparison covers tablet versus injection properly, and live prices for every option sit across the network on Monj, iGovy and Ogovy. Whatever you choose, eligibility and a proper consultation come first: start with our BMI and licence guide.